Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 1
Submit an article Journal homepage
810
Views
17
CrossRef citations to date
0
Altmetric
Original Articles: Research

Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment*

Jan de JongJanssen Research & Development, San Diego, CA, USA; Correspondence[email protected]
,
Donna SkeeJanssen Research & Development, Raritan, NJ, USA;
,
Peter HellemansJanssen Research & Development, Beerse, Belgium;
,
James JiaoJanssen Research & Development, Raritan, NJ, USA;
,
Ronald de VriesJanssen Research & Development, Beerse, Belgium;
,
Dominique SwertsJanssen Research & Development, Beerse, Belgium;
,
Eric LawitzTexas Liver Institute, University of Texas Health Science CenterSan Antonio, TX, USA;
,
Thomas MarburyOrlando Clinical Research Center, Orlando, FL, USA;
,
William SmithNew Orleans Center for Clinical Research, Knoxville, TN, USA;
,
Juthamas SukbuntherngPharmacyclics LLC, Sunnyvale, CA, USA
&
Erik MannaertJanssen Research & Development, Beerse, Belgium;
show all
Pages 185-194 | Received 10 Feb 2016, Accepted 08 May 2016, Published online: 07 Jun 2016

References

  • Akinleye A, Chen Y, Mukhi N, et al. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013;6:59.
  • Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA. 2010;107:13075–13080.
  • Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–516.
  • Imbruvica prescribing information; [cited 2016 Jan 28]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205552lbl.pdf
  • Imbruvica™. Product monograph: Bruton’s Tyrosine Kinase (BTK) inhibitor. [cited 2016 Jan 28]. Available from: https://www.janssenmd.com/pdf/imbruvica/PI-Imbruvica.pdf
  • Parmar S, Patel K, Pinilla-Ibarz J. Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. P&T. 2014;39:483–519.
  • de Vries R, Huang M, Bode N, et al. Bioanalysis of ibrutinib and its active metabolite in human plasma: selectivity issue, impact assessment and resolution. Bioanalysis. 2015;7:2713–2724.
  • Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
  • O'Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15:48–58.
  • Byrd JC, Blum KA, Burger JA, et al. Activity and tolerability of the Bruton’s tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): interim results of a phase Ib/II study [abstract]. J Clin Oncol. 2011;29:6508.
  • Byrd JC, Furman RR Coutre SE, et al. The Bruton's tyrosine kinase(BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): interim results of a phase Ib/II study[abstract]. J Clin Oncol. 2012;30:6507.
  • O'Brien S, Burger JA, Blum KA, et al. The Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up of a phase Ib/II study [abstract]. ASH Annu Meet. 2011. (supplement). Abstract 983.
  • Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.
  • Imbruvica™. Summary of product information EMA. [cited 2016 Jan 28]. Available from: http://www.medicines.org.uk/emc/medicine/29383
  • de Jong J, Sukbuntherng J, Skee D, et al. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol. 2015;75:907–916.
  • Marostica E, Sukbuntherng J, Loury D, et al. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies. Cancer Chemother Pharmacol. 2015;75:111–121.
  • Sukbuntherng J, Jejurkar P, Chan S, et al. Pharmacokinetics (PK) of ibrutinib in patients with chronic lymphocytic leukemia (CLL) [abstract]. J Clin Oncol. 2013;31:7056.
  • de Jong J, Skee D, Murphy J, et al. Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants. Pharmacol Res Perspect. 2015;3:e00156.
  • Mackichan JJ. Influence of protein binding and use of unbound (free) drug concentrations. In: Burton ME, Shaw LM, Schentag JJ, Evans WE, editors Applied pharmacokinetics and pharmacodynamics–principles of therapeutic drug monitoring. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 82–120.
  • De Zwart L, Snoeys J, De Jong J, et al. Physiologically based pharmacokinetic (PBPK) modelling to determine the drug-drug interaction (DDI) potential for CYP3A perpetrators during ibrutinib therapy[Poster]. ACCP. 2015.
  • Johnson TN, Boussery K, Rowland-Yeo K, et al. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 2010;49:189–206.
  • Imbruvica. Clinical pharmacology and biopharmaceutics review(s). [cited 2016 Jan 28]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205552Orig1s000ClinPharmR.pdf.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.